Bavarian Nordic vaccine helps prolong life in prostate cancer trial
Tuesday, February 24, 2015 - 15:00
in Health & Medicine
(Reuters) - An experimental therapeutic vaccine from Danish drugmaker Bavarian Nordic helped significantly extend survival in patients with advanced prostate cancer, according to results of a small early-stage trial conducted by the U.S. National Cancer Institute.